Patents Assigned to Array Biopharma Inc.
  • Bicyclic inhibitors of MEK and methods of use thereof
    Patent number: 7485643
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 3, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Joseph P. Lyssikatos, Hong Woon Yang
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 7452895
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: November 18, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 7449486
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: November 11, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R Laird, John Robinson, Shelley Allen
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 7425637
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 16, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Compounds and methods of use
    Patent number: 7425631
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 16, 2008
    Assignees: Amgen Inc., Array BioPharma Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, Jr., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
    Publication number: 20070299063
    Abstract: Disclosed are amino acid prodrugs of compounds of the formula I and pharmaceutically acceptable salts thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 14, 2007
    Publication date: December 27, 2007
    Applicant: Array BioPharma, Inc.
    Inventors: Eli Wallace, Joseph Lyssikatos, Allison Marlow, T. Hurley, Kevin Koch
  • Capreomycin derivatives and their use as antibacterials
    Patent number: 7294616
    Abstract: The present subject matter relates to phenylurea capreomycin derivatives, and to metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present subject matter are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present subject matter also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial infections by administering such compounds. The present subject matter also relates to methods of preparing such compounds.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: November 13, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Joseph P. Lyssikatos, Steven Mark Wenglowsky
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7271178
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R11 and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: September 18, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Eli M. Wallace, James Blake
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 7235537
    Abstract: Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 26, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley, Kevin Koch
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7230099
    Abstract: Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: June 12, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Eli Wallace, Brian Hurley, Hong Woon Yang, Joseph Lyssikatos, Jim Blake, Alison Marlow
  • Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
    Patent number: 7226906
    Abstract: Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: June 5, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Kevin W. Hunt, Laurence E. Burgess
  • Cyclic amine derivatives and methods of use
    Patent number: 7199244
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: April 3, 2007
    Assignees: Amgen, Array Biopharma Inc.
    Inventors: Robert D. Groneberg, James Zhan, Benny C. Askew, Jr., Derin C. D'Amico, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Jiawang Zhu, Kevin Yang, Jian Jeffrey Chen, Rana Nomak
  • Dipeptidyl peptidase inhibitors
    Patent number: 7169926
    Abstract: Compounds are provided which may be used to inhibit DPP-IV comprising the formula: wherein the substituents are as described in the specification and claims.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: January 30, 2007
    Assignees: Takeda Pharmaceutical Company Limited, Array BioPharma Inc.
    Inventors: Laurence E. Burgess, Scott D. Cowen, Stephen L. Gwaltney, II, Jeongboeb Seo, Jeffrey A. Stafford
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7144907
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: December 5, 2006
    Assignee: Array Biopharma Inc.
    Inventors: Eli Wallace, Brian Hurley, Hon Woon Yang, Joseph Lyssikatos, Jim Blake
  • Method of structure-based drug design to create or improve modulators of IL-1 activity which bind to the interleukin-1 type 1 receptor
    Patent number: 7144988
    Abstract: Crystals comprising a modified interleukin-1 type 1 receptor (IL-1R1) and one or more modulators of IL-1 activity are described. Methods of identifying potential inhibitors of IL-1 activity are also described. Compositions and methods for the treatment of IL-1 mediated diseases, such as rheumatoid arthritis, osteoarthritis, and other inflammatory conditions, are described.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: December 5, 2006
    Assignee: Array Biopharma, Inc.
    Inventors: Barbara J. Brandhuber, Guy P. A. Vigers
  • P38 inhibitors and methods of use thereof
    Patent number: 7135575
    Abstract: This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: November 14, 2006
    Assignee: Array BioPharma, Inc.
    Inventors: Mark Munson, James Rizzi, Martha Rodriguez, Ganghyeok Kim
  • Preparation of phosphatase inhibitors
    Patent number: 7078425
    Abstract: Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, and R4 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: July 18, 2006
    Assignee: Array Biopharma Inc.
    Inventors: Robert D. Groneberg, David A. Mareska
  • Isocyano substituted polystyrene carbonate resin for use in 3 and 4 component condensation reactions
    Patent number: 6911554
    Abstract: This invention relates to compounds comprising isocyano derivatives tethered to solid supports for use in 3 and 4 component condensation reactions. The invention also relates to methods for synthesizing cyclic derivatives by a 3 and 4 component condensation reaction using the compounds of the invention.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 28, 2005
    Assignee: Array Biopharma Inc.
    Inventors: April Kennedy, John A. Josey
  • Method of structure-based drug design to create or improve modular of IL-1 activity which mind to the interleukin-1 type 1 receptor
    Publication number: 20040014643
    Abstract: Crystals comprising a modified interleukin-1 type 1 receptor (IL-1R1) and one or more modulators of IL-1 activity are described. Methods of identifying potential inhibitors of IL-1 activity are also described. Compositions and methods for the treatment of IL-1 mediated diseases, such as rheumatoid arthritis, osteoarthritis, and other inflammatory conditions, are described.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 22, 2004
    Applicant: Array BioPharma Inc.
    Inventors: Barbara J. Brandhuber, Guy P.A. Vigers
  • Preparation of phosphatase inhibitors
    Patent number: 6586467
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: July 1, 2003
    Assignee: Array BioPharma Inc.
    Inventors: Laurence E. Burgess, John J. Gaudino, Robert D. Groneberg, Mark H. Norman, Martha E. Rodriguez, Xicheng Sun, Eli M. Wallace